

Review Article



Personalized Pain Pathways in Liver Fibrosis: Towards Precision Hepatology

Tamer A. Addissouky^{1,2,3,4*} 

¹Medical Laboratories Techniques Department, College of Technology and Health Sciences, AL-Mustaqbal University, 51001, Hillah, Babylon, Iraq

²Department of Biochemistry, Science Faculty, Menoufia University, Menoufia, Egypt

³New burg El-Arab Hospital, Ministry of Health, Alexandria, Egypt

⁴American Society for Clinical Pathology (ASCP), Chicago, USA

Article history:

Received: August 10, 2024

Revised: August 27, 2024

Accepted: August 28, 2024

ePublished: December 31, 2024

*Corresponding author:

Tamer A. Addissouky,

Emails: tedesoky@gmail.com;

tedesoky@science.menofia.edu.eg

Abstract

Liver fibrosis, characterized by excessive accumulation of extracellular matrix (ECM), is a critical precursor to cirrhosis and hepatocellular carcinoma. While the liver itself lacks pain fibers, fibrosis progression can induce pain through various mechanisms, significantly impacting patient quality of life and potentially influencing disease outcomes. This review aims to elucidate the complex relationship between liver fibrosis and pain, exploring recent advances in pain assessment, management strategies, and emerging therapies. The pathophysiology of liver fibrosis involves intricate cellular and molecular mechanisms, with hepatic stellate cell (HSC) activation playing a central role. Pain in liver fibrosis arises from capsular distension, inflammation-induced nociception, and neuropathic pain. Recent advances in pain assessment include the exploration of biomarkers, advanced imaging techniques, and liver-specific patient-reported outcome measures. Current management strategies encompass pharmacological approaches with liver-specific considerations, non-pharmacological interventions, and complementary medicine. Emerging therapies, including novel antifibrotic agents, targeted pain therapies, and regenerative medicine approaches, offer promising avenues for addressing both fibrosis and associated pain. However, challenges persist in balancing pain relief with the preservation of liver function and managing altered drug metabolism in liver disease. The future of pain management in liver fibrosis lies in personalized approaches, integrating pain management into comprehensive liver care and exploring the potential of fibrosis reversal for pain relief. As our understanding of the molecular mechanisms underlying both liver fibrosis and pain deepens, targeted therapies addressing patient-specific pain pathways while simultaneously targeting fibrosis progression may become a reality.

Keywords: Liver fibrosis, Chronic liver pain, Hepatic stellate cells, Antifibrotic therapies, Nociception in liver disease, Personalized pain management, Fibrosis reversal



Please cite this article as follows: Addissouky TA. Personalized pain pathways in liver fibrosis: towards precision hepatology. Avicenna J Med Biochem. 2024; 12(2):162-171. doi:10.34172/ajmb.2535

Background

Liver fibrosis is a complex pathological process characterized by the excessive accumulation of extracellular matrix (ECM) proteins in response to chronic liver injury (1). This progressive condition represents a critical juncture in the spectrum of chronic liver diseases, serving as a precursor to cirrhosis and potentially hepatocellular carcinoma (2). The etiology of liver fibrosis is diverse, encompassing viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), autoimmune disorders, and metabolic diseases (3). As fibrosis advances, it disrupts the normal liver architecture, impairs hepatic function, and alters intrahepatic hemodynamics, leading

to a cascade of systemic complications (4). The relationship between pain and liver fibrosis is multifaceted and often underappreciated in clinical practice. While the liver itself lacks pain fibers, the progression of fibrosis can induce pain through various mechanisms, including capsular distension, inflammation-mediated nociception, and neuropathic alterations. Pain in liver fibrosis is not merely a symptom but a complex phenomenon that interacts with the underlying disease process, potentially influencing its progression and patient outcomes (5).

Elucidating the mechanisms of pain in liver fibrosis is crucial for several reasons. First, it enables the development of targeted therapies that address both the underlying



fibrotic process and the associated pain, potentially improving patients' quality of life and treatment adherence (6). Second, a deeper understanding of pain pathways in liver disease may reveal novel insights into the progression of fibrosis itself, as inflammatory and nociceptive processes often share common mediators. Lastly, accurate assessment and management of pain in liver fibrosis patients can inform clinical decision-making, helping to balance the need for pain relief with the imperative to preserve liver function and prevent further hepatic injury (7).

Pathophysiology of Liver Fibrosis

Cellular and Molecular Mechanisms

The pathogenesis of liver fibrosis involves a complex interplay of cellular and molecular events. At the core of this process are hepatic stellate cells (HSCs), which undergo activation in response to liver injury. Activated HSCs transform from quiescent vitamin A-storing cells into myofibroblast-like cells capable of producing large amounts of ECM proteins, primarily type I and III collagens. This activation is orchestrated by a variety of cytokines and growth factors, including transforming growth factor- β (TGF- β), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF) (8). Chronic liver injury, triggered by factors such as NAFLD, NASH, and DILI, activates various parenchymal and non-parenchymal cells, initiating cellular and molecular pathways that promote hepatic inflammation through the production of diverse inflammatory mediators. This excessive inflammation drives the activation of HSCs, which subsequently transform into proliferative myofibroblasts capable of producing ECM, ultimately leading to fibrosis and hepatic dysfunction. Key players in this process include KCs, which produce inflammatory factors such as TGF- β , TNF- α , and TIM-4, as well as IRF-5 and NLRP3, which contribute to the inflammatory cascade and subsequent fibrotic response as depicted in Figure 1 (9).

Progression from Inflammation to Fibrosis

The transition from acute inflammation to chronic fibrosis is a critical step in liver disease progression. Persistent hepatic injury, regardless of etiology, leads to a sustained inflammatory response characterized by the recruitment of immune cells and the release of pro-inflammatory mediators. This chronic inflammation creates a microenvironment conducive to fibrogenesis, with continuous activation of HSCs and other fibrogenic cell populations. The balance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) becomes dysregulated, favoring ECM accumulation over degradation (10).

Key Mediators and Signaling Pathways

Several key signaling pathways and mediators are involved in the fibrotic process. The TGF- β /Smad pathway is central to fibrogenesis, promoting HSC activation and collagen production. Other important pathways include the PDGF signaling axis, which stimulates HSC proliferation, and the Wnt/ β -catenin pathway, which contributes to HSC activation and survival. Recent research has also highlighted the role of epigenetic modifications, such as DNA methylation and histone modifications, in the activation of HSCs. Additionally, the renin-angiotensin system (RAS) has been implicated in liver fibrosis, with angiotensin II promoting HSC activation and fibrogenesis (11).

Pain in Liver Fibrosis

Prevalence and Characteristics of Pain in Liver Disease

Pain is a common and often debilitating symptom in patients with liver fibrosis and cirrhosis, with prevalence estimates ranging from 30% to 79% depending on the study population and disease etiology. The characteristics of pain in liver disease are diverse, including localized right upper quadrant pain, diffuse abdominal discomfort, and referred pain to the shoulder or back. The intensity and quality of pain can vary widely, from a dull persistent ache




Figure 1. Cellular and Molecular Mechanisms in Chronic Liver Injury-induced Fibrosis. Reprinted from Khanam et al (9) under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

to acute severe episodes. Notably, the relationship between pain severity and the degree of liver fibrosis is not always linear, suggesting complex underlying mechanisms (12). The rationale for studying pain management in chronic liver disease, particularly in early stages like fibrosis, warrants clarification. Pain can significantly impact the quality of life of patients even in the early stages of the disease. Understanding the mechanisms of pain in liver fibrosis could provide insights into disease progression and potential therapeutic targets (13). Early pain management strategies might improve outcomes and delay progression by addressing factors such as inflammation and stellate cell activation. Reporting the accurate prevalence of pain in liver fibrosis, distinct from end-stage liver disease data, is crucial (14). Furthermore, studying pain in liver fibrosis could lead to the development of more sensitive diagnostic tools or biomarkers for disease progression, enhancing our understanding and management of this condition (15).

Mechanisms of Pain in Liver Fibrosis

The pain pathway in liver fibrosis involves complex mechanisms. Capsular distension triggers nociceptors in Glisson's capsule. Inflammation activates pain receptors through cytokines and prostaglandins. Neuropathic pain arises from metabolic disturbances and direct neurotoxicity. Central sensitization alters pain processing. Visceral hypersensitivity enhances pain perception. HSC activation contributes to fibrogenesis and inflammation (16). Pro-inflammatory mediators sensitize peripheral nerves. Altered gut-brain axis influences pain signaling. Oxidative stress damages nerve fibers. Microglial activation in the CNS amplifies pain signals. Substance P and calcitonin gene-related peptide modulate nociception. Endocannabinoid system dysregulation affects pain perception. Portal hypertension exacerbates mechanical stress. Cytokine cascades perpetuate inflammatory pain (17). Neuroplasticity in chronic liver disease modifies

pain pathways. Immune cell infiltration contributes to local and systemic hyperalgesia. Altered pain thresholds result from prolonged nociceptive input. Autonomic nervous system dysfunction influences pain processing. Endothelial dysfunction affects microcirculation and nociceptor function (18).

1. Capsular Distension

One of the primary mechanisms of pain in liver fibrosis is capsular distension. As fibrosis progresses, the liver may enlarge, stretching the Glisson's capsule that surrounds the organ as depicted in Table 1. This capsule is innervated by pain fibers, and its distension can lead to a dull aching pain in the right upper quadrant. Capsular distension can be exacerbated by hepatic congestion due to portal hypertension or the presence of liver masses, such as regenerative nodules or hepatocellular carcinoma (19).

2. Inflammation-Induced Nociception

Chronic inflammation plays a crucial role in both the progression of liver fibrosis and the generation of pain. Pro-inflammatory cytokines such as tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6) can sensitize nociceptors and lower the pain threshold. These mediators can act both locally within the liver and systemically, contributing to a state of generalized hyperalgesia. Moreover, the release of bradykinin, prostaglandins, and other inflammatory mediators can directly activate nociceptive nerve endings in the peritoneum and surrounding tissues (20).

3. Neuropathic Pain

Emerging evidence suggests that liver fibrosis may also involve neuropathic pain mechanisms. Chronic liver disease can lead to peripheral neuropathy through various pathways, including metabolic disturbances, vitamin deficiencies, and direct neurotoxicity from substances such as alcohol or hepatitis C virus. This neuropathy

Table 1. Mechanisms of Pain in Liver Fibrosis

Mechanism	Description	Key mediators	Clinical manifestations	Potential therapeutic targets
Capsular distension	Stretching of Glisson's capsule due to liver enlargement	Mechanical stress, Portal hypertension, Hepatomegaly	Dull aching pain in the right upper quadrant, Pain exacerbated by physical activity or deep breathing	Antifibrotic agents to reduce liver size, Portal pressure-lowering drugs
Inflammation-induced nociception	Activation and sensitization of nociceptors by inflammatory mediators	TNF- α , IL-1 β , IL-6, bradykinin, prostaglandins	Diffuse abdominal pain, Hyperalgesia, Allodynia	Anti-inflammatory drugs, Cytokine inhibitors, Prostaglandin synthesis inhibitors
Neuropathic pain	Damage to peripheral nerves due to metabolic disturbances or direct neurotoxicity	Oxidative stress, Vitamin deficiencies, Alcohol-induced, neurotoxicity, Hepatitis C virus	Burning or shooting pain, Tingling sensations, Pain in extremities	Antioxidants, Vitamin supplementation, Gabapentinoids, Antiviral therapy for HCV
Central sensitization	Altered pain processing in the central nervous system	Neuroplasticity, Glial cell activation, Neurotransmitter imbalance	Widespread pain, Reduced pain threshold, Cognitive and emotional changes	NMDA receptor antagonists, Glial cell modulators, Cognitive behavioral therapy
Visceral hypersensitivity	Enhanced perception of visceral stimuli	Altered gut-brain axis, Intestinal barrier dysfunction, Microbiome dysbiosis	Increased sensitivity to normal visceral stimuli, Bloating and discomfort	Probiotics, Intestinal barrier enhancers, Neuromodulators

may manifest as burning, tingling, or shooting pains, particularly in the extremities. Additionally, central sensitization processes in the spinal cord and brain may contribute to altered pain processing in chronic liver disease, potentially amplifying pain perception and contributing to the development of chronic pain syndromes (21-23).

Impact of Pain on Quality of Life and Disease Progression

The presence of pain in liver fibrosis significantly impacts patients' quality of life, affecting physical functioning, emotional well-being, and social interactions. Chronic pain can lead to sleep disturbances, fatigue, and mood disorders, further exacerbating the overall disease burden. Moreover, pain may influence disease progression through various mechanisms. Pain-related stress can activate the hypothalamic-pituitary-adrenal axis and sympathetic nervous system, potentially modulating immune function and inflammation. Additionally, pain may lead to reduced physical activity and altered dietary habits, which can negatively impact liver health and overall metabolic status (24).

Recent Advances in Pain Assessment in Liver Fibrosis Biomarkers for Pain in Liver Disease

Recent research has focused on identifying biomarkers that can objectively quantify pain in liver disease. Serum levels of substance P, a neuropeptide involved in pain signaling, have been investigated as a potential biomarker for pain intensity in cirrhotic patients. Similarly, plasma levels of endocannabinoids, which play a role in pain modulation, have been shown to be correlated with pain scores in liver disease. Emerging metabolomic and proteomic approaches are being explored to develop comprehensive pain management protocols that could differentiate between nociceptive and neuropathic pain in liver fibrosis (25).

Imaging Techniques for Pain Evaluation

Advanced imaging modalities provide new insights into pain mechanisms in liver fibrosis. Functional magnetic resonance imaging (fMRI) studies have revealed altered brain activation patterns in response to painful stimuli in patients with chronic liver disease, suggesting central nervous system changes in pain processing. Positron emission tomography (PET) with specific radiotracers has been used to visualize neuroinflammation and microglial activation, which may contribute to pain sensitization in liver disease. Additionally, elastography techniques, while primarily used to assess liver stiffness, may provide indirect information about capsular tension and its relationship to pain (26).

Patient-Reported Outcome Measures Specific to Liver Disease-Related Pain

The development of validated liver-specific patient-

reported outcome measures (PROMs) has significantly improved the assessment of pain in liver fibrosis. The Chronic Liver Disease Questionnaire (CLDQ) includes pain-specific domains that capture the unique aspects of liver-related pain. More recently, the Liver Disease Symptom Index 2.0 (LDSI 2.0) has been developed to provide a more comprehensive evaluation of symptoms, including pain, in chronic liver disease. These tools not only enhance clinical assessment but also facilitate standardized reporting in research studies, enabling better comparisons across interventions and patient populations (27).

Current Management Strategies for Pain in Liver Fibrosis

Pharmacological Approaches

1. Analgesics and Their Liver-Specific Considerations

The pharmacological management of pain in liver fibrosis requires careful consideration of drug metabolism and potential hepatotoxicity. Acetaminophen remains the first-line analgesic for mild to moderate pain, but dosing should be adjusted based on liver function, typically not exceeding 2-3 g/d in patients with advanced liver disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are generally avoided due to their potential to exacerbate portal hypertension and increase the risk of bleeding. For more severe pain, opioids may be considered, but their use is complicated by altered drug metabolism in liver disease and the risk of precipitating hepatic encephalopathy (28). Demographic factors such as age, gender, and ethnicity modulate nociceptive pathways, pain perception, and analgesic responses in patients with hepatic fibrosis. Pharmacogenomics, comorbidities, and sociocultural factors necessitate the development of individualized multimodal analgesia considering these demographic variations. Pain management in patients with hepatic disease necessitates judicious opioid prescribing, mitigating the risk of addiction/overdose. Ethical deliberations weigh adequate analgesia versus potential substance use disorder, diversion hazards, and burdens of restrictive monitoring protocols (29).

2. Anti-inflammatory Agents

Given the role of inflammation in both liver fibrosis progression and pain generation, anti-inflammatory agents represent a rational therapeutic approach as depicted in Table 2. Corticosteroids may be used in specific etiologies of liver disease, such as autoimmune hepatitis, providing both anti-inflammatory and analgesic effects. However, their long-term use is limited by significant side effects. Targeted anti-cytokine therapies, such as anti-TNF- α agents, have shown promise in the treatment of certain liver diseases and may indirectly alleviate pain by modulating the inflammatory milieu (30).

3. Antifibrotic Treatments With Potential Pain-Relieving Effects

Table 2. Current and Emerging Therapies for Pain Management in Liver Fibrosis

Category	Therapy	Mechanism of action	Benefits	Limitations/considerations	Stage of development
Pharmacological approaches	Acetaminophen	Inhibits prostaglandin synthesis in the CNS	First-line for mild to moderate pain, Relatively safe in liver disease	Dose adjustment required, Max 2-3g/day in advanced liver disease	Established
	NSAIDs	Inhibit cyclooxygenase enzymes	Effective pain relief	Generally avoided due to risk of portal hypertension and bleeding, Potential for hepatotoxicity	Limited use in liver disease
	Opioids	Activate opioid receptors in CNS	Effective for severe pain	Altered metabolism in liver disease, Risk of hepatic encephalopathy, Potential for addiction and hyperalgesia	Used with caution
	Corticosteroids	Broad anti-inflammatory effects	Pain relief, Antifibrotic in some etiologies (e.g., autoimmune hepatitis)	Long-term side effects, Limited use in chronic liver disease	Established for specific indications
Antifibrotic agents	Anti-TNF- α agents	Inhibit tumor necrosis factor- α	Reduces inflammation, Potential anti-fibrotic effects	Immunosuppression, High cost	Investigational for liver fibrosis
	Obeticholic acid	Farnesoid X receptor agonist	Anti-fibrotic effects, Potential pain relief in some patients	Limited data on pain outcomes, Side effects (e.g., pruritus)	Approved for PBC/ investigational for NASH
	Cannabinoid receptor modulators	Modulate endocannabinoid system	Potential anti-fibrotic and analgesic effects	Psychoactive effects, Regulatory challenges	Preclinical/early clinical
Non-pharmacological Interventions	Physical therapy and exercise	Multiple mechanisms	Improves physical conditioning, Potential anti-fibrotic effects	Limited by patient's physical condition, Requires long-term adherence	Established
	Cognitive-behavioral therapy	Alters pain perception and coping strategies	Improves pain management, Addresses comorbid psychological conditions	Requires patient engagement, Limited availability	Established
	Mindfulness-based stress reduction	Alters pain perception through meditation and awareness	Reduces pain intensity and improves quality of life	Requires patient commitment, Variable efficacy	Growing evidence
Complementary approaches	Acupuncture	Modulates pain pathways	Potential pain relief and improved quality of life	Limited high-quality evidence in liver disease, Practitioner variability	Investigational
	Herbal medicines	Various mechanisms	Potential anti-fibrotic and analgesic effects	Risk of hepatotoxicity, Lack of standardization	Varies by specific agent
Emerging therapies	ASK1 inhibitors	Inhibit apoptosis signal-regulating kinase 1	Reduces liver fibrosis and inflammation, Potential indirect analgesic effect	Limited data on pain outcomes	Late-stage clinical trials
	Galectin-3 inhibitors	Inhibit a protein involved in fibrogenesis	Potential anti-fibrotic and anti-inflammatory effects	Limited data on pain outcomes	Early clinical trials
	TRP channel antagonists	Block transient receptor potential channels	Potential anti-fibrotic effects, Direct analgesic effects	Limited data on liver disease	Preclinical/early clinical
	Probiotics and microbiome-based therapies	Modulate gut-liver axis	Potential to reduce systemic inflammation and pain	Variable efficacy, Strain-specific effects	Investigational
Gene and cell therapies	RNA interference technologies	Target key fibrogenic pathways	Potential to halt or reverse fibrosis	Delivery challenges, Limited long-term safety data	Preclinical/early clinical
	Mesenchymal stem cell therapy	Promote liver regeneration and modulate inflammation	Potential for fibrosis reversal and pain relief	Standardization issues, Long-term safety concerns	Early clinical trials

Several antifibrotic agents under investigation for liver fibrosis have demonstrated potential pain-relieving properties. For instance, obeticholic acid, a farnesoid X receptor agonist approved for primary biliary cholangitis, has shown improvements in pruritus and potentially

pain in some patients. Similarly, cannabinoid receptor modulators, being studied for their antifibrotic effects, may offer analgesic benefits through their actions on the endocannabinoid system. As our understanding of the shared pathways between fibrosis and pain grows, future

antifibrotic therapies may be developed with dual actions on both processes (31).

Non-pharmacological Interventions

Incorporating cognitive-behavioral therapy, mindfulness, and psychoeducation alongside pharmacotherapy optimizes biopsychosocial pain management in patients with liver fibrosis. Interdisciplinary approaches ameliorate pain catastrophizing, depression, anxiety, and medication adherence, thereby enhancing quality of life and treatment efficacy.

1. Physical Therapy and Exercise

Physical therapy and structured exercise programs play an increasingly recognized role in managing pain associated with liver fibrosis. Targeted exercises can help alleviate musculoskeletal pain often accompanying chronic liver disease, improve overall physical condition, and potentially reduce the perception of visceral pain. Specific techniques such as manual therapy and posture correction may be particularly beneficial for patients experiencing pain related to hepatomegaly or ascites. Moreover, regular physical activity has been shown to have antifibrotic effects, potentially addressing both pain and underlying liver disease (32).

2. Psychological Interventions

The psychological components of chronic pain in liver fibrosis are significant but often underaddressed. Cognitive-behavioral therapy (CBT) has emerged as an effective intervention for managing pain perception and improving coping strategies in patients with chronic liver disease. Mindfulness-based stress reduction techniques have also shown promise in reducing pain intensity and improving quality of life. These psychological approaches not only target pain directly but also address comorbid conditions such as depression and anxiety, which are common in liver fibrosis and can exacerbate pain (33-37).

3. Complementary and Alternative Medicine Approaches

Various complementary and alternative medicine (CAM) approaches have been explored for pain management in liver fibrosis. Acupuncture has shown potential in reducing pain and improving quality of life in some studies of patients with chronic liver disease. Herbal medicines, particularly those derived from traditional Chinese medicine, are being investigated for their potential antifibrotic and analgesic properties. However, caution is warranted due to the potential hepatotoxicity of some herbal preparations. Other CAM modalities, such as massage therapy and yoga, may offer symptomatic relief and improve overall well-being; however, more rigorous studies are needed to establish their efficacy specifically in liver fibrosis-related pain (38).

Emerging Therapies and Research Directions

Novel Antifibrotic Agents and Their Impact on Pain

The landscape of antifibrotic therapy for liver disease is rapidly evolving, with several promising agents in late-

stage clinical trials. These novel therapies, while primarily targeting the fibrotic process, may have significant implications for pain management. For instance, inhibitors of apoptosis signal-regulating kinase 1 (ASK1) have shown potential in reducing liver fibrosis and inflammation, which could indirectly alleviate pain. Similarly, selective inhibitors of galectin-3, a protein involved in fibrogenesis and inflammation, are being investigated for their antifibrotic properties and may offer pain relief through modulation of inflammatory pathways (39-44).

Targeted Pain Therapies for Liver Disease

Research is increasingly focusing on developing pain therapies specifically tailored to the unique pathophysiology of liver disease. One promising avenue is the targeting of transient receptor potential (TRP) channels, which are involved in both nociception and HSC activation. Antagonists of transient receptor potential vanilloid 1 (TRPV1), for example, are being explored for their potential to reduce both liver fibrosis and associated pain. Another area of interest is the modulation of the gut-liver axis, with probiotics and microbiome-based therapies showing the potential to reduce systemic inflammation and alleviate pain in liver disease (45).

Gene Therapy and Regenerative Medicine Approaches

Cutting-edge approaches in gene therapy and regenerative medicine offer exciting prospects for both liver fibrosis reversal and pain management. RNA interference technologies targeting key fibrogenic pathways are in the early stage of development and may provide a means to halt or reverse fibrosis while potentially addressing pain mechanisms. Stem cell therapies, particularly mesenchymal stem cells, are being investigated for their ability to promote liver regeneration and modulate inflammation, which could have significant implications for pain relief. Additionally, gene editing techniques, such as CRISPR-Cas9, are opening up possibilities for correcting genetic defects underlying certain liver diseases, potentially addressing both the root cause of fibrosis and associated pain syndromes (46-51).

Challenges of Pain Management in Patients With Liver Fibrosis

Balancing Pain Relief With Liver Function Preservation

One of the primary challenges in managing pain in liver fibrosis patients is striking a balance between adequate pain relief and preservation of liver function. Many analgesics undergo hepatic metabolism, and their pharmacokinetics can be significantly altered in the setting of liver disease. This necessitates careful dose adjustments and monitoring to avoid drug accumulation and potential hepatotoxicity. Moreover, some pain management strategies that might be effective in other conditions may be contraindicated in liver disease due to their potential to exacerbate portal hypertension or precipitate hepatic decompensation (52).

Drug Metabolism Alterations in Liver Disease

The altered drug metabolism in liver disease presents a significant challenge in pain management. Hepatic impairment can affect both phase I (oxidation, reduction, and hydrolysis) and phase II (conjugation) metabolic pathways, leading to unpredictable drug levels and increased risk of adverse effects. The prescription of opioid analgesics for the management of pain in patients with liver diseases is problematic as they may accumulate in the liver, lead to oversedation, or precipitate hepatic encephalopathy. Additionally, the reduced synthesis of plasma proteins in advanced liver disease can affect drug binding and distribution, further complicating dosing strategies. Clinicians must carefully consider these pharmacokinetic alterations when selecting and dosing pain medications in liver fibrosis patients (53-56).

Risk of Opioid-Induced Hyperalgesia and Addiction

The use of opioids in liver fibrosis patients is fraught with challenges beyond altered metabolism. Opioid-induced hyperalgesia, a paradoxical increase in pain sensitivity with prolonged opioid use, may be more pronounced in liver disease due to altered central pain processing. This phenomenon can lead to a cycle of escalating opioid doses with diminishing analgesic efficacy. Furthermore, the risk of opioid addiction is a significant concern, particularly given the potential for impaired judgment and decision-making in patients with hepatic encephalopathy. Balancing effective pain control with the risk of opioid-induced hyperalgesia requires careful patient selection, close monitoring, and often a multimodal approach to pain management (57).

Economic Implications

Comprehensive pain management strategies for patients with liver fibrosis entail substantial direct medical costs (pharmacotherapies, interventions), indirect costs (disability, absenteeism), and intangible costs (diminished quality of life). Cost-effectiveness analyses comparing multimodal approaches versus standard care inform resource allocation decisions (58).

Personalized Pain Management Strategies

Tailored Treatment Strategies

The development of personalized pain management strategies for patients with liver fibrosis involves tailoring pain management strategies to individual patients based on their unique disease characteristics, genetic profiles, and pain experiences. This approach integrates biomarker analysis, advanced imaging techniques, and patient-reported outcomes to create targeted treatment plans. Clinicians consider factors such as fibrosis stage, etiology, comorbidities, and pain mechanisms when designing interventions (59).

Integrating Genetic and Phenotypic Data

Genetic testing may reveal polymorphisms affecting pain

sensitivity or drug metabolism. Personalized therapies might combine pharmacological approaches with lifestyle modifications, psychological interventions, and emerging antifibrotic treatments (60-61). Machine learning algorithms could help predict individual pain trajectories and treatment responses (62).

Precision Medicine for Optimal Outcomes

This precision medicine approach aims to optimize pain relief while minimizing side effects and addressing underlying fibrosis progression. Ongoing research focuses on developing more sophisticated tools for pain phenotyping and personalized drug selection in liver fibrosis patients (63).

Conclusion

This comprehensive review elucidates the intricate relationship between liver fibrosis and pain, highlighting the multifaceted nature of pain mechanisms in chronic liver disease. The findings underscore the importance of a holistic approach to pain management in patients with liver fibrosis, integrating both pharmacological and non-pharmacological interventions tailored to the unique pathophysiology of liver disease. Emerging antifibrotic therapies and targeted pain management strategies show promise in addressing both the underlying fibrotic process and associated pain syndromes. The potential for fibrosis reversal opens new avenues for pain relief, potentially alleviating mechanical and inflammatory sources of pain. However, significant challenges remain, particularly in balancing effective pain control with the preservation of liver function and managing the altered drug metabolism in liver disease. The complexity of pain in liver fibrosis, coupled with the heterogeneity of patient populations and disease etiologies, limits the generalizability of current management strategies. Additionally, the long-term efficacy and safety of novel therapies require further investigation in large-scale clinical trials.

Recommendations

Future research should focus on developing personalized pain management approaches that account for individual patient factors, disease etiology, and stage of liver fibrosis. There is a pressing need for large-scale longitudinal studies to evaluate the long-term efficacy and safety of emerging antifibrotic therapies and their impact on pain outcomes. Efforts should be directed towards identifying reliable biomarkers for pain in liver disease, which could facilitate more objective pain assessment and treatment monitoring. The integration of artificial intelligence and machine learning algorithms into clinical decision-making tools could enhance the prediction of individual pain trajectories and treatment responses. Furthermore, the development of liver-specific formulations of analgesics that minimize hepatotoxicity while maintaining efficacy should be prioritized. Multidisciplinary collaborations between hepatologists, pain specialists, and basic scientists

should be encouraged to accelerate the translation of basic research findings into clinical practice. Finally, patient education programs should be expanded to empower individuals with liver fibrosis to take an active role in their pain management, incorporating self-management strategies and promoting adherence.

Competing Interests

There is no conflicts of interests relevant to this article.

Ethical Approval

Not applicable.

Funding

None.

References

- Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. *Cells*. 2020;9(4):875. doi: [10.3390/cells9040875](https://doi.org/10.3390/cells9040875).
- Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y. Transforming screening, risk stratification, and treatment optimization in chronic liver disease through data science and translational innovation. *Indones J Gastroenterol Hepatol Dig Endosc*. 2024;25(1):53-62. doi: [10.24871/251202453-62](https://doi.org/10.24871/251202453-62).
- Addissouky T, Ali MM, El Tantawy El Sayed I, Alubiady MH. Realizing the promise of artificial intelligence in hepatocellular carcinoma through opportunities and recommendations for responsible translation. *Jurnal Online Informatika*. 2024;9(1):70-9. doi: [10.15575/join.v9i1.1297](https://doi.org/10.15575/join.v9i1.1297).
- Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. Bending the curve through innovations to overcome persistent obstacles in HIV prevention and treatment. *J AIDS HIV Treat*. 2024;6(1):44-53. doi: [10.33696/aids.6.051](https://doi.org/10.33696/aids.6.051).
- Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. *World J Gastroenterol*. 2020;26(2):109-33. doi: [10.3748/wjg.v26.i2.109](https://doi.org/10.3748/wjg.v26.i2.109).
- Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. *Schisandra chinensis* in liver disease: exploring the mechanisms and therapeutic promise of an ancient Chinese botanical. *Arch Pharmacol Ther*. 2024;6(1):27-33. doi: [10.33696/pharmacol.6.052](https://doi.org/10.33696/pharmacol.6.052).
- Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y. Type 1 diabetes mellitus: retrospect and prospect. *Bull Natl Res Cent*. 2024;48(1):42. doi: [10.1186/s42269-024-01197-z](https://doi.org/10.1186/s42269-024-01197-z).
- Elpek GÖ. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update. *World J Gastroenterol*. 2014;20(23):7260-76. doi: [10.3748/wjg.v20.i23.7260](https://doi.org/10.3748/wjg.v20.i23.7260).
- Khanam A, Saleeb PG, Kottlilil S. Pathophysiology and treatment options for hepatic fibrosis: can it be completely cured? *Cells*. 2021;10(5):1097. doi: [10.3390/cells10051097](https://doi.org/10.3390/cells10051097).
- Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y. Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis. *Egypt J Intern Med*. 2024;36(1):19. doi: [10.1186/s43162-024-00283-y](https://doi.org/10.1186/s43162-024-00283-y).
- Addissouky TA, El Tantawy El Sayed I, Ali MM, Wang Y, El Baz A, Elarabany N, et al. Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting. *Bull Natl Res Cent*. 2024;48(1):16. doi: [10.1186/s42269-024-01174-6](https://doi.org/10.1186/s42269-024-01174-6).
- Peng JK, Hepgul N, Higginson IJ, Gao W. Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis. *Palliat Med*. 2019;33(1):24-36. doi: [10.1177/0269216318807051](https://doi.org/10.1177/0269216318807051).
- Holman A, Parikh N, Clauw DJ, Williams DA, Tapper EB. Contemporary management of pain in cirrhosis: toward precision therapy for pain. *Hepatology*. 2023;77(1):290-304. doi: [10.1002/hep.32598](https://doi.org/10.1002/hep.32598).
- Yilmaz Y, Toraman AE, Alp C, Doğan Z, Keklikkiran C, Stepanova M, et al. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study. *Aliment Pharmacol Ther*. 2023;57(2):215-23. doi: [10.1111/apt.17301](https://doi.org/10.1111/apt.17301).
- Kushner T, Lange M, Argiriadi PA, Meislin R, Sigel K, Terrault N. Prevalence, risk profiles, and national implications of nonalcoholic fatty liver disease in pregnant individuals. *Clin Gastroenterol Hepatol*. 2024;22(1):194-6.e1. doi: [10.1016/j.cgh.2023.03.031](https://doi.org/10.1016/j.cgh.2023.03.031).
- Zhang CY, Liu S, Yang M. Treatment of liver fibrosis: past, current, and future. *World J Hepatol*. 2023;15(6):755-74. doi: [10.4254/wjh.v15.i6.755](https://doi.org/10.4254/wjh.v15.i6.755).
- Zhang X, Zeng Y, Zhao L, Xu Q, Miao D, Yu F. Targeting hepatic stellate cell death to reverse hepatic fibrosis. *Curr Drug Targets*. 2023;24(7):568-83. doi: [10.2174/1389450124666230330135834](https://doi.org/10.2174/1389450124666230330135834).
- Tao L, Yang G, Sun T, Jie T, Zhu C, Yu H, et al. Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1. *J Hepatol*. 2023;78(4):805-19. doi: [10.1016/j.jhep.2022.12.031](https://doi.org/10.1016/j.jhep.2022.12.031).
- Klinge M, Coppler T, Liebschutz JM, Dugum M, Wassan A, DiMartini A, et al. The assessment and management of pain in cirrhosis. *Curr Hepatol Rep*. 2018;17(1):42-51. doi: [10.1007/s11901-018-0389-7](https://doi.org/10.1007/s11901-018-0389-7).
- Lowe KO, Tanase CE, Maghami S, Fisher LE, Ghaemmaghami AM. Inflammatory network of liver fibrosis and how it can be targeted therapeutically. *Immuno*. 2023;3(4):375-408. doi: [10.3390/immuno3040023](https://doi.org/10.3390/immuno3040023).
- Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. Recent developments in the diagnosis, treatment, and management of cardiovascular diseases through artificial intelligence and other innovative approaches. *J Biomed Res*. 2024;5(1):29-40. doi: [10.46439/biomedres.5.041](https://doi.org/10.46439/biomedres.5.041).
- Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. Transforming glomerulonephritis care through emerging diagnostics and therapeutics. *J Biomed Res*. 2024;5(1):41-52. doi: [10.46439/biomedres.5.043](https://doi.org/10.46439/biomedres.5.043).
- Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. *Front Endocrinol (Lausanne)*. 2023;14:1265372. doi: [10.3389/fendo.2023.1265372](https://doi.org/10.3389/fendo.2023.1265372).
- Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues Clin Neurosci*. 2006;8(4):383-95. doi: [10.31887/DCNS.2006.8.4/ssmith](https://doi.org/10.31887/DCNS.2006.8.4/ssmith).
- Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. *Nat Rev Neurol*. 2020;16(7):381-400. doi: [10.1038/s41582-020-0362-2](https://doi.org/10.1038/s41582-020-0362-2).
- Edin C, Ekstedt M, Karlsson M, Wegmann B, Wartjes M, Swahn E, et al. Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis. *Eur Radiol*. 2024;34(11):7492-502. doi: [10.1007/s00330-024-10798-1](https://doi.org/10.1007/s00330-024-10798-1).
- Winkelmann C, Mezentseva A, Vogt B, Neumann T. Patient-reported outcome measures in liver and gastrointestinal cancer randomized controlled trials. *Int J Environ Res Public Health*. 2023;20(13):6293. doi: [10.3390/ijerph20136293](https://doi.org/10.3390/ijerph20136293).

28. Rubin JB, Aby ES, Barman P, Tincopa M. Opioid use and risks in candidates and recipients of liver transplant. *Liver Transpl.* 2024. doi: [10.1097/lvt.0000000000000388](https://doi.org/10.1097/lvt.0000000000000388).
29. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. *Mayo Clin Proc.* 2010;85(5):451-8. doi: [10.4065/mcp.2009.0534](https://doi.org/10.4065/mcp.2009.0534).
30. Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et al. Liver fibrosis: therapeutic targets and advances in drug therapy. *Front Cell Dev Biol.* 2021;9:730176. doi: [10.3389/fcell.2021.730176](https://doi.org/10.3389/fcell.2021.730176).
31. Guo YC, Lu LG. Antihepatic fibrosis drugs in clinical trials. *J Clin Transl Hepatol.* 2020;8(3):304-12. doi: [10.14218/jcth.2020.00023](https://doi.org/10.14218/jcth.2020.00023).
32. Jafarikhah R, Damirchi A, Rahmani Nia F, Razavi-Toosi SM, Shafaghi A, Asadian M. Effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver. *Sci Rep.* 2023;13(1):15475. doi: [10.1038/s41598-023-42687-w](https://doi.org/10.1038/s41598-023-42687-w).
33. Addissouky TA. Polyploidy-mediated resilience in hepatic aging: molecular mechanisms and functional implication. *Egyptian Liver Journal* 2024;14(1):83. doi: [10.1186/s43066-024-00391-y](https://doi.org/10.1186/s43066-024-00391-y).
34. Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. Towards personalized care: unraveling the genomic and molecular basis of sepsis-induced respiratory complications. *Arch Clin Toxicol.* 2024;6(1):4-15. doi: [10.46439/toxicology.6.026](https://doi.org/10.46439/toxicology.6.026).
35. Addissouky TA, El Tantawy El Sayed I, Ali MM, Alubiady MH, Wang Y. Harnessing innovation for the future of breast cancer management. *Clin Res Oncol.* 2024;1(1):10-7. doi: [10.46439/Oncology.1.004](https://doi.org/10.46439/Oncology.1.004).
36. Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. Risk factors, etiology, pathology, and diagnostic methods for acute kidney injury: a review study. *Res Mol Med.* 2022;10(4):193-204. doi: [10.32598/rmm.10.4.1265.1](https://doi.org/10.32598/rmm.10.4.1265.1).
37. Polis S, Fernandez R. Impact of physical and psychological factors on health-related quality of life in adult patients with liver cirrhosis: a systematic review protocol. *JBI Database System Rev Implement Rep.* 2015;13(1):39-51. doi: [10.11124/jbisrir-2015-1987](https://doi.org/10.11124/jbisrir-2015-1987).
38. Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, et al. Complementary and alternative medicine use in chronic liver disease patients. *J Clin Gastroenterol.* 2010;44(2):e40-5. doi: [10.1097/MCG.0b013e3181b766ed](https://doi.org/10.1097/MCG.0b013e3181b766ed).
39. Addissouky TA, El Tantawy El Sayed I, Ali MM, Wang Y, El Baz A, Elarabany N, et al. Shaping the future of cardiac wellness: exploring revolutionary approaches in disease management and prevention. *J Clin Cardiol.* 2024;5(1):6-29. doi: [10.33696/cardiology.5.048](https://doi.org/10.33696/cardiology.5.048).
40. Addissouky TA, El Tantawy El Sayed I, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. *Egypt Liver J.* 2024;14(1):2. doi: [10.1186/s43066-023-00306-3](https://doi.org/10.1186/s43066-023-00306-3).
41. Addissouky T, Ali MM, El Tantawy El Sayed I, Wang Y. Revolutionary innovations in diabetes research: from biomarkers to genomic medicine. *Iran J Diabetes Obes.* 2023;15(4):228-42. doi: [10.18502/ijdo.v15i4.14556](https://doi.org/10.18502/ijdo.v15i4.14556).
42. Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y, Khalil AA. Translational insights into molecular mechanisms of chemical hepatocarcinogenesis for improved human risk assessment. *Adv Clin Toxicol.* 2024;9(1):294. doi: [10.23880/act-16000294](https://doi.org/10.23880/act-16000294).
43. Addissouky TA, Wang Y, El Tantawy El Sayed I, Ali MM, Khalil AA. Emerging technologies and advanced biomarkers for enhanced toxicity prediction and safety pharmacology. *Adv Clin Toxicol.* 2024;9(1):293. doi: [10.23880/act-16000293](https://doi.org/10.23880/act-16000293).
44. Jangra A, Kothari A, Sarma P, Medhi B, Omar BJ, Kaushal K. Recent advancements in antifibrotic therapies for regression of liver fibrosis. *Cells.* 2022;11(9):1500. doi: [10.3390/cells11091500](https://doi.org/10.3390/cells11091500).
45. Majid M, Yahya M, Ansah Owusu F, Bano S, Tariq T, Habib I, et al. Challenges and opportunities in developing tailored pain management strategies for liver patients. *Cureus.* 2023;15(12):e50633. doi: [10.7759/cureus.50633](https://doi.org/10.7759/cureus.50633).
46. Addissouky TA, Wang Y, El Tantawy El Sayed I, Ali MM, Khalil AA. Transforming toxicity assessment through microphysiology, bioprinting, and computational modeling. *Adv Clin Toxicol.* 2024;9(1):295. doi: [10.23880/act-16000295](https://doi.org/10.23880/act-16000295).
47. Addissouky TA, El Tantawy El Sayed I, Ali MM. Regenerating damaged joints: the promise of tissue engineering and nanomedicine in lupus arthritis. *Clinical Orthopaedics and Trauma Care.* 2024;6(2):1-8. doi: [10.31579/2694-0248/083](https://doi.org/10.31579/2694-0248/083).
48. Addissouky TA, El Tantawy El Sayed I, Ali MM. Conservative and emerging rehabilitative approaches for knee osteoarthritis management. *Clinical Orthopaedics and Trauma Care.* 2024;6(2):1-11. doi: [10.31579/2694-0248/082](https://doi.org/10.31579/2694-0248/082).
49. Addissouky TA, El Tantawy El Sayed I, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Can vaccines stop cancer before it starts? Assessing the promise of prophylactic immunization against high-risk preneoplastic lesions. *J Cell Immunol.* 2023;5(4):127-40. doi: [10.33696/immunology.5.178](https://doi.org/10.33696/immunology.5.178).
50. Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y. Recent advances in diagnosing and treating *Helicobacter pylori* through botanical extracts and advanced technologies. *Arch Pharmacol Ther.* 2023;5(1):53-66. doi: [10.33696/Pharmacol.4.045](https://doi.org/10.33696/Pharmacol.4.045).
51. Salazar-Montes AM, Hernández-Ortega LD, Lucano-Landeros MS, Armendariz-Borunda J. New gene therapy strategies for hepatic fibrosis. *World J Gastroenterol.* 2015;21(13):3813-25. doi: [10.3748/wjg.v21.i13.3813](https://doi.org/10.3748/wjg.v21.i13.3813).
52. Hamilton JP. Pain management in liver disease. *Gastroenterol Hepatol (N Y).* 2023;19(6):355-8.
53. Addissouky TA, Ali MM, El Tantawy El Sayed I, Wang Y, El Baz A, Elarabany N, et al. Preclinical promise and clinical challenges for innovative therapies targeting liver fibrogenesis. *Arch Gastroenterol Res.* 2023;4(1):14-23. doi: [10.33696/Gastroenterology.4.044](https://doi.org/10.33696/Gastroenterology.4.044).
54. Addissouky TA, Wang Y, El Tantawy El Sayed I, El Baz A, Ali MM, Khalil AA. Recent trends in *Helicobacter pylori* management: harnessing the power of AI and other advanced approaches. *Beni Suef Univ J Basic Appl Sci.* 2023;12(1):80. doi: [10.1186/s43088-023-00417-1](https://doi.org/10.1186/s43088-023-00417-1).
55. Addissouky TA, Wang Y, El Tantawy El Sayed I, Khalil AA. Probiotics and diet modifications: a holistic approach to tackling *Helicobacter pylori* with the help of the gut microbiota. *Res Sq [Preprint].* July 11, 2023. Available from: <https://www.researchsquare.com/article/rs-3139132/v1>.
56. Armani S, Geier A, Forst T, Merle U, Alpers DH, Lunnon MW. Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: impact on pharmacokinetics and drug-drug interactions. *Br J Clin Pharmacol.* 2024;90(4):942-58. doi: [10.1111/bcp.15990](https://doi.org/10.1111/bcp.15990).
57. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? *Curr Pain Headache Rep.* 2011;15(2):129-36. doi: [10.1007/s11916-010-0171-1](https://doi.org/10.1007/s11916-010-0171-1).
58. de Almeida Cardoso MM, Thabane L, Romeiro FG, Silva GF, Machado-Rugolo J, Fonseca AF, et al. Economic evaluation of non-invasive liver tests for the diagnosis of liver fibrosis in

- chronic liver diseases: a systematic review protocol. *JBI Evid Synth.* 2024;22(4):681-8. doi: [10.11124/jbies-23-00097](https://doi.org/10.11124/jbies-23-00097).
59. Ferreira do Couto ML, Fonseca S, Pozza DH. Pharmacogenetic approaches in personalized medicine for postoperative pain management. *Biomedicines.* 2024;12(4):729. doi: [10.3390/biomedicines12040729](https://doi.org/10.3390/biomedicines12040729).
60. Raad M, López WO, Sharafshah A, Assefi M, Lewandrowski KU. Personalized medicine in cancer pain management. *J Pers Med.* 2023;13(8):1201. doi: [10.3390/jpm13081201](https://doi.org/10.3390/jpm13081201).
61. De Rosa F, Giannatiempo B, Charlier B, Coglianese A, Mensitieri F, Gaudino G, et al. Pharmacological treatments and therapeutic drug monitoring in patients with chronic pain. *Pharmaceutics.* 2023;15(8):2088. doi: [10.3390/pharmaceutics15082088](https://doi.org/10.3390/pharmaceutics15082088).
62. Zmudzki F, Smeets R. Machine learning clinical decision support for interdisciplinary multimodal chronic musculoskeletal pain treatment. *Front Pain Res (Lausanne).* 2023;4:1177070. doi: [10.3389/fpain.2023.1177070](https://doi.org/10.3389/fpain.2023.1177070).
63. Valenzuela-Vallejo L, Sanoudou D, Mantzoros CS. Precision medicine in fatty liver disease/non-alcoholic fatty liver disease. *J Pers Med.* 2023;13(5):830. doi: [10.3390/jpm13050830](https://doi.org/10.3390/jpm13050830).